Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study - Wikidata - wikimedia - TriplyDB

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study

http://www.wikidata.org/entity/Q36880729

about

Extended-spectrum beta-lactamases: a clinical update Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa Clinical management of infections caused by multidrug-resistant Enterobacteriaceae Carbapenems Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain.Extended-spectrum beta-lactamases and clinical outcomes: current data.Imipenem resistance of Pseudomonas in pneumonia: a systematic literature review Clinical pharmacodynamics of cefepime in patients infected with Pseudomonas aeruginosa.SHV-type extended-spectrum beta-lactamase production is associated with Reduced cefepime susceptibility in Enterobacter cloacae A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa.ESBLs: A Clear and Present Danger?Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms.Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.Global spread of multiple aminoglycoside resistance genes.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.Study on imipenem resistance and prevalence of blaVIM1 and blaVIM2 metallo-beta lactamases among clinical isolates of Pseudomonas aeruginosa from Mashhad, Northeast of Iran.The continuing challenge of ESBLs.Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update.Treatment of Pseudomonas aeruginosa infection in critically ill patients.Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults.The current state of multidrug-resistant gram-negative bacilli in North America.Cefepime: a reappraisal in an era of increasing antimicrobial resistance.The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.The role of carbapenems in initial therapy for serious Gram-negative infections.Phenotypic characterization of ESBL producing Enterobacter cloacae among children.AmpC beta-lactamases.Nephrotoxicity of cefepime: A new cephalosporin antibiotic in rats Treatment of multidrug-resistant Gram-negative infections in children.Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.The growing threat of multidrug-resistant Gram-negative infections in patients with hematologic malignancies.Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study.Cefepime Therapy for Cefepime-Susceptible Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bacteremia.A randomized open label study of 'imipenem vs. cefepime' in spontaneous bacterial peritonitis.

P2860

Q24534999-E3DBE025-E48C-4785-8C44-5C611CF6936C Q24612271-F3D39146-ABF0-4BC6-8238-FC857C88F43A Q28246841-0676CF0D-CA21-40C5-8AF1-13B55D8A931F Q28286055-6A139FE4-D6F7-4064-8628-AB06A92843CD Q28299749-1060C95C-0872-4E91-9856-EFF4B78228B2 Q30396308-840ABBCA-C3BB-423E-A7A7-BB9B601A34E9 Q33236875-8EAB27C9-8597-44D4-8E43-C500FE612181 Q33675546-8DF04140-6C97-4AF7-A3B9-2129C69D4F69 Q33676227-F0BA710F-E977-486C-B798-9006DF0900A0 Q34073514-8E33862A-90AE-4014-9E5C-A4CABC2A4520 Q34414748-5418E6A8-705A-4E26-A0EB-3F7DC8D2BACE Q34555131-36E4C938-45D0-49D7-88EA-5F7264B14D48 Q35101453-36600178-B86A-4214-A3BA-FF46E8AF1E53 Q35356144-4BF23A5E-C065-45E7-B9D4-2189F87939B5 Q35867313-55391F22-06A3-4D77-9B03-92372E34A495 Q36009396-FCFEA1FA-65B3-4657-BCA2-67F7BBDF5D6D Q36078359-A97366C3-EF89-4F6D-98D2-96AF22C8D3DB Q36086501-6D5E4680-D9E3-42A1-8610-91C29EEB2DF3 Q36327325-DF6732A7-2718-4828-8466-162E3B04FC58 Q36449603-2BA6F8FC-1302-460A-8B5B-1ABF5FEF578A Q36474366-C89EC2ED-CDFB-4DB9-923F-C8C12FBA8C73 Q36607415-28AD7F93-DD57-488B-9E10-5E7C5DF8318D Q37029217-012EC1A0-043D-42D4-8808-E0E9E3DAA637 Q37069191-03F3887C-E038-4E31-A8E0-957B4DDFE4EB Q37079350-60E74309-4FB0-424B-BB14-47A6847FCE8A Q37098999-A649D8D9-3B3C-4F27-A128-AAE1233EC376 Q37169849-EF962559-3D47-427D-9AB8-4D713FB87DA2 Q37257813-292C3E55-563B-4F04-9A61-A184B2983BA1 Q37366249-60542455-90AE-4486-941D-4CF24E450CFA Q37565871-28A25D51-8E17-4B0D-BF90-96C0DD16ACA9 Q38185648-D15408F5-0428-4632-8717-7A3C4FC87317 Q38620812-997E87CC-59DC-4DA5-9B7F-694A3700A811 Q38739545-1A0D29D0-CDCB-4245-B39C-01681AA33E19 Q38792841-0D76AEC5-2B0F-4A02-B746-08013E7E596E Q38864569-360E78F6-F1B9-440E-B217-21A53BB0794D Q38875315-2CBDC051-4462-48BC-B74A-ECD0000F637D Q38981397-F43CB202-336C-4780-9C7D-354614EA99C4 Q39773769-A8027111-AAE5-4AAE-AE7C-B623639A6067 Q40612416-B5059BE4-8DFD-4F9E-A7D9-7836E5F8A3A5 Q41209156-F94E03F3-E1BC-4D22-A186-752CA06C4D91

P2860

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study

http://www.wikidata.org/entity/Q36880729

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Cefepime versus imipenem-cilas ...... prospective, randomized study

@en

type

label

Cefepime versus imipenem-cilas ...... prospective, randomized study

@en

prefLabel

Cefepime versus imipenem-cilas ...... prospective, randomized study

@en

P1433

Q36880729-B5A6603B-44C5-45A8-B51E-BE2A25617C1F

P1476

Q36880729-AB10FEBB-8503-4676-A017-7F61459C9A20

P2093

Q36880729-0E66D53B-F353-4AF8-8120-23631799D97B

Q36880729-102C2186-9416-4AB3-AD93-7D19281DAD4D

Q36880729-176A4542-28AD-42BC-9B02-719F6EB98584

Q36880729-1862E66E-EB67-4044-A59E-C562CE50D14A

Q36880729-22157411-301B-431A-BE9F-AED46D6BF014

Q36880729-295457E6-C504-421C-88E7-0121445A72E7

Q36880729-394908F3-2D7A-4D39-8386-30130372D458

Q36880729-80CEB392-20AD-4364-B52A-247551C6F61E

Q36880729-81202550-6601-4A6D-9162-3DD66A6FBE4C

Q36880729-826FB327-5E4E-4767-8908-65664B14F5F2

P2860

Q36880729-00A0DA70-BB7C-4D22-A57E-4EF8B0413ADF

Q36880729-03346375-9A12-4023-A55C-00BFE7965E33

Q36880729-0D1ACC73-A595-4530-A0A8-4C7B74A363B7

Q36880729-3A520B22-2A2C-408C-8315-121C81C7657B

Q36880729-401567ED-C9BC-4008-8F62-BD346C562F4E

Q36880729-499F76BC-5D06-48A6-A927-F4CEC8F5A968

Q36880729-4D2B853E-A9B8-4B92-949E-EB53762F96CA

Q36880729-5D430F26-41DB-4FCC-A479-459035A78DA0

Q36880729-6131082B-C1D8-4643-998C-6802E1EF18E2

Q36880729-7BB4A47B-67E8-4FB5-BEB0-E8CC4E78502C

P304

Q36880729-FAFFFAE7-BA98-463E-B304-B44D66FC1ABB

P31

Q36880729-838F35E3-E1DD-4A0B-8E8C-912955E51506

P356

Q36880729-9F3FFA7F-4A4F-459A-9856-C1D20542B304

P407

Q36880729-96ACFA17-0597-4BF4-93E2-370080330FB6

P433

Q36880729-25B22BDD-476C-421F-ABAA-FA886A10E20E

P478

Q36880729-D87704A8-D809-4355-96EB-33C8E69E4DAE

P50

Q36880729-7D7D7C1B-AB2B-4AE4-BAA3-A00BC5EA2332

P577

Q36880729-6BBF969D-452B-4D59-8407-90325578F239

P698

Q36880729-11D9AAFC-EB96-47E8-BA7B-FDF009A6F727

P921

Q36880729-466AC859-0D05-4D3D-87BD-4FAF88177E5D

Q36880729-82EC13C7-F703-4371-B308-B46C2447ED5F

Q36880729-BA2F0BD9-77E2-4DA0-B18D-46A5FA17F923

P932

Q36880729-7A628282-6F16-4B3D-8623-E4E9DD654FFF

P356

AAC.47.11.3442-3447.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

Cefepime versus imipenem-cilas ...... prospective, randomized study

@en

P2093

A Cometta

http://www.w3.org/2001/XMLSchema#string

Cefepime Study Group,

http://www.w3.org/2001/XMLSchema#string

D Aymon

http://www.w3.org/2001/XMLSchema#string

D Lew

http://www.w3.org/2001/XMLSchema#string

E Rubinstein

http://www.w3.org/2001/XMLSchema#string

F Bally

http://www.w3.org/2001/XMLSchema#string

G Zanetti

http://www.w3.org/2001/XMLSchema#string

J Bille

http://www.w3.org/2001/XMLSchema#string

J Garbino

http://www.w3.org/2001/XMLSchema#string

J-A Romand

http://www.w3.org/2001/XMLSchema#string

P2860

Ventilator-associated pneumonia

Hospital-acquired pneumonia. Attributable mortality and morbidity.

Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients.

Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.

Cefepime: the next generation?

Mortality of nosocomial pneumonia in ventilated patients: influence of diagnostic tools.

A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia.

Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns.

P304

3442-3447

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.11.3442-3447.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14576100

http://www.w3.org/2001/XMLSchema#string

P921

intensive care unit

multicenter trial

P932

253800

http://www.w3.org/2001/XMLSchema#string